Skip to content

Study · Randomized controlled trial · n = 30 · 2022

14 results

Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.

Xie D, Li Y, Xu M, Zhao X, Chen M

Cardiovascular diabetology3 Oct 2022Cited by 33 (Europe PMC)

PMID36199064 (opens in a new tab)PMCIDPMC9533545 (opens in a new tab)DOI10.1186/s12933-022-01634-1 (opens in a new tab)PepBankPUB-36199064
Download PDFPubMedAsk about this study
Jump to 14 results

Summary

BackgroundRandomised controlled trial showed that dulaglutide can reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM), but the underlying mechanisms remain unclear. This study aimed to investigate the effect of dulaglutide on the number and function of endothelial progenitor cells (EPCs) in the peripheral blood of patients with T2DM and its role in improving arterial elasticity, so as to determine potential mechanisms of preventive effect of dulaglutide on ASCVD.MethodsSixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30). Before and after treatment, the number of CD34+CD133+KDR+ EPCs and the brachial-ankle pulse wave velocity (baPWV) of the participants were measured, and EPC proliferation, adhesion, migration, and tubule formation were assessed in vitro.ResultsThere were no significant differences in the number and function of EPCs and baPWV changes in MET group (P > 0.05). In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05). EPC proliferation, adhesion, migration, and tubule formation abilities were significantly enhanced (P < 0.05). Correlation analysis showed that in MET-DUL group, the changes in CRP, IL-6, TNF-α, and AGEs were negatively correlated with the number of EPCs and their proliferation and migration abilities (P < 0.05). Body weight, NO, CRP, and IL-6 levels were independent factors affecting the number of EPCs (P < 0.05). The changes in number of EPCs, proliferation and migration abilities of EPCs, and NO and IL-6 levels were independent influencing factors of baPWV changes (P < 0.05).ConclusionDulaglutide can increase the number and function of EPCs in peripheral blood and improve arterial elasticity in patients with T2DM; it is accompanied by weight loss, inflammation reduction, and high NO levels. Dulaglutide regulation of EPCs may be a mechanism of cardiovascular protection.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study14

11 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In diabetes patients receiving metformin and dulaglutide, nitric oxide levels increased from pretreatment.

    In plain wordsNitric oxide levels increased after dulaglutide treatment with background metformin compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseNitric oxide levels
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In diabetes patients receiving metformin and dulaglutide, endothelial progenitor cell numbers increased from pretreatment.

    In plain wordsBlood vessel progenitor cell numbers increased after dulaglutide treatment with background metformin compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseEndothelial progenitor cell number
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In diabetes patients receiving metformin and dulaglutide, C-reactive protein levels decreased from pretreatment.

    In plain wordsC-reactive protein decreased after dulaglutide treatment with background metformin compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseC-reactive protein
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In diabetes patients receiving metformin and dulaglutide, interleukin-6 levels decreased from pretreatment.

    In plain wordsInterleukin-6 decreased after dulaglutide treatment with background metformin compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInterleukin-6
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In diabetes patients receiving metformin and dulaglutide, tumour necrosis factor-α levels decreased from pretreatment.

    In plain wordsTumour necrosis factor decreased after dulaglutide treatment with background metformin compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTumour necrosis factor-α
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In diabetes patients receiving metformin and dulaglutide, advanced glycation end products decreased from pretreatment.

    In plain wordsAdvanced glycation end products decreased after dulaglutide treatment with background metformin compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAdvanced glycation end products
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In diabetes patients receiving metformin and dulaglutide, brachial-ankle pulse wave velocity decreased from pretreatment.

    In plain wordsArterial stiffness decreased after dulaglutide treatment with background metformin compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBrachial-ankle pulse wave velocity
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05).
    2 context sentences
    Summary · context
    Before and after treatment, the number of CD34+CD133+KDR+ EPCs and the brachial-ankle pulse wave velocity (baPWV) of the participants were measured, and EPC proliferation, adhesion, migration, and tubule formation were assessed in vitro.
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In isolated cells from diabetes patients receiving metformin and dulaglutide, EPC tubule formation increased after treatment.

    In plain wordsIn patients receiving dulaglutide with metformin, sampled blood vessel progenitor cells formed more tubules after treatment than before treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseEPC tubule formation
    Study

    n = 30

    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    EPC proliferation, adhesion, migration, and tubule formation abilities were significantly enhanced (P < 0.05).
    2 context sentences
    Summary · context
    Before and after treatment, the number of CD34+CD133+KDR+ EPCs and the brachial-ankle pulse wave velocity (baPWV) of the participants were measured, and EPC proliferation, adhesion, migration, and tubule formation were assessed in vitro.
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  9. 09LabEx vivo tissueEfficacy outcome

    In isolated cells from diabetes patients receiving metformin and dulaglutide, EPC proliferation increased after treatment.

    In plain wordsIn lab tests, cells from patients receiving dulaglutide with metformin showed greater proliferation after treatment than before treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseEPC proliferation
    Study

    humann = 30

    Peripheral blood endothelial progenitor cells from T2DM patients
    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    EPC proliferation, adhesion, migration, and tubule formation abilities were significantly enhanced (P < 0.05).
    2 context sentences
    Summary · context
    Before and after treatment, the number of CD34+CD133+KDR+ EPCs and the brachial-ankle pulse wave velocity (baPWV) of the participants were measured, and EPC proliferation, adhesion, migration, and tubule formation were assessed in vitro.
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  10. 10LabEx vivo tissueEfficacy outcome

    In isolated cells from diabetes patients receiving metformin and dulaglutide, EPC adhesion increased after treatment.

    In plain wordsIn lab tests, cells from patients receiving dulaglutide with metformin showed greater adhesion after treatment than before treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseEPC adhesion
    Study

    humann = 30

    Peripheral blood endothelial progenitor cells from T2DM patients
    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    EPC proliferation, adhesion, migration, and tubule formation abilities were significantly enhanced (P < 0.05).
    2 context sentences
    Summary · context
    Before and after treatment, the number of CD34+CD133+KDR+ EPCs and the brachial-ankle pulse wave velocity (baPWV) of the participants were measured, and EPC proliferation, adhesion, migration, and tubule formation were assessed in vitro.
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).
  11. 11LabEx vivo tissueEfficacy outcome

    In isolated cells from diabetes patients receiving metformin and dulaglutide, EPC migration increased after treatment.

    In plain wordsIn lab tests, cells from patients receiving dulaglutide with metformin showed greater migration after treatment than before treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseEPC migration
    Study

    humann = 30

    Peripheral blood endothelial progenitor cells from T2DM patients
    Comparator
    Pretreatment in MET-DUL group
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    EPC proliferation, adhesion, migration, and tubule formation abilities were significantly enhanced (P < 0.05).
    2 context sentences
    Summary · context
    Before and after treatment, the number of CD34+CD133+KDR+ EPCs and the brachial-ankle pulse wave velocity (baPWV) of the participants were measured, and EPC proliferation, adhesion, migration, and tubule formation were assessed in vitro.
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism

    In metformin-dulaglutide recipients, inflammatory and glycation marker changes correlated negatively with EPC number, proliferation and migration changes.

    In plain wordsDuring combined treatment, marker changes were negatively linked to changes in blood vessel progenitor cell number and function.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInflammatory and glycation marker associations with EPC changes
    Study

    n = 30

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Correlation analysis showed that in MET-DUL group, the changes in CRP, IL-6, TNF-α, and AGEs were negatively correlated with the number of EPCs and their proliferation and migration abilities (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism

    In diabetes patients, body weight, nitric oxide, C-reactive protein and interleukin-6 were independent factors affecting EPC number.

    In plain wordsBody weight and the reported marker levels were independently linked to blood vessel progenitor cell number.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedIndependent factors affecting EPC number
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Body weight, NO, CRP, and IL-6 levels were independent factors affecting the number of EPCs (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 14HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism

    In diabetes patients, EPC number, proliferation, migration, nitric oxide and interleukin-6 changes independently influenced pulse wave velocity changes.

    In plain wordsChanges in progenitor cells and the reported markers were independently linked to arterial stiffness changes.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedIndependent factors affecting arterial stiffness change
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    The changes in number of EPCs, proliferation and migration abilities of EPCs, and NO and IL-6 levels were independent influencing factors of baPWV changes (P < 0.05).
    1 context sentence
    Summary · context
    Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30).

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.